DISCOVERIES (ISSN 2359-7232), 2019, January-March issue

CITATION: 

Submitted: March 18th, 2019; Revised: March 28th, 2019; Accepted: March 28th, 2019; Published: March 31st, 2019; 

 GO BACK to 2019, January-March issue

 GO BACK to DISCOVERIES

Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem

Diana Ruxandra Florescu *, Diana Elena Nistor *

Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;

*Corresponding authors: Diana Ruxandra  Florescu and Diana Elena  Nistor,  Faculty  of  Medicine,  Carol Davila  University  of  Medicine  and  Pharmacy,  Bucharest,  Romania;  Emails: dianarflorescu@yahoo.comand nistordiana94@gmail.com respectively.

Abstract

Breast cancer is the second most commonly diagnosed cancer, being one of the main health issues that needs to be addressed worldwide. New therapies have led to a remarkable increase in survival rates, which is unfortunately overshadowed by their negative impact on cardiac structure and function in disease-free patients. Since anthracyclines and trastuzumab cause the most undesired outcome in breast cancer patients - cardiac-related mortality, they have been widely studied. However, other therapies (such as hormonal therapy, tyrosine kinase inhibitors, anti-VEGF drugs etc.) can also affect the cardiovascular system and lead to ischemia, hypertension or vascular thromboembolism. Even though excessive research has been conducted in thepast decades, there are still no guidelines regarding the most adequate methods neither to detect and prevent severe cardiotoxicity that can finally lead to heart failure and ultimately death nor for the further management of patients after cardiotoxicity is detected. Biomarkers of ischemia (troponins T and I) and of overload (BNP and NT-proBNP) in association with periodic echocardiographies (assessment of the global longitudinal strain) are two of the most important means used by physicians in the evaluation of cardiac disease in this group of patients. Given that no internationally accepted guidelines for screening and surveillance of different populations exist, the cardio-oncology team is crucial in the management of these patients, their collaboration resulting in individualized treatment regimens. After careful evaluation of different variables (treatment effects, malignancy status, and the patient's pre-existing conditions), a decision is made to either reduce the dosage or rate of administration, change the medication or interrupt the treatment and initiate the cardioprotective therapeutic associations. Consequently, it is an absolute necessity the development of customized treatment guidelines and the conduction of multiple clinical studies in order to demonstrate their effect on long-term survival.

Access full text of the manuscript here: Full text (pdf)

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009.
3. Marwick TH. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues. Can J Cardiol. 2016;32(7):842-846.
4. Ezaz G, Long JB, Gross CP, Chen J. Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. J Am Heart Assoc. 2014;3(1).
5. Clark RA, Marin TS, Berry NM, Atherton JJ, Foote JW, Koczwara B. Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment. Cardio-Oncology. 2017;3(1):6.
6. Hon JDC, Singh B, Sahin A, et al. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864-1872.
7. Cardoso F, Senkus E, Costa A, et al. Clinical Practice Guidelines Slideset Advanced Breast Cancer.; 2018. https://www.esmo.org/content/download/181639/3308758/file/Clinical-Practice-Guidelines-Slideset-Advanced-Breast-Cancer.pdf. Accessed March 6, 2019.
8. Curigliono G, Cardinale D, Dent S, et al. Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management. CA Cancer J Clin. 2016 Jul;66(4):309-25.
9. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl. 5):277-282.
10. Navarrete S. Cancer and cardiotoxicity in women. Rev Colomb Cardiol. 2018;25:144-153.
11. Hamo CE, Bloom MW, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 2: Prevention, treatment, guidelines, and future directions. Circ Hear Fail. 2016 Feb;9(2):e002843.
12. Feldman AM, Michl K, Konstam MA, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. J Am Coll Cardiol. 2009;53(15):e1-e90.
13. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.
14. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-1093.
15. Clasen SC, Wald JW. Left Ventricular Dysfunction and Chemotherapeutic Agents. Curr Cardiol Rep. 2018 Mar 8;20(4):20.
16. Cao L, Zhu W, Wagar EA, Meng QH. Biomarkers for monitoring chemotherapy-induced cardiotoxicity. Crit Rev Clin Lab Sci. 2017 Mar;54(2):87-101.
17. Lin C, Chen LS, Kuo SJ, Chen DR. Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast Care. 2014 Feb;9(1):35-9.
18. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.
19. Valachis A, Nilsson C. Cardiac risk in the treatment of breast cancer: Assessment and management. Breast Cancer Targets Ther. 2015;7:21-35.
20. Hiscox S, Davies EL, Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas. 2009 Aug 20;63(4):275-9.
21. Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70.
22. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W et la. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006 Aug;7(8):633-43.
23. Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:3845.
24. https://www.cancer.org/cancer/breast-cancer/treatment.html. Accesed in March 2019.
25. Bloom MW, Hamo CE, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Hear Fail. 2016 Jan;9(1):e002661.
26. Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. In: Journal of Clinical Oncology 2015 Apr 1;33(10):1136-42.
27. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20;29(6):632-8.
28. Des Guetz G, Uzzan B, Chouahnia K, Morère JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011 Dec;6(4):197-202.
29. Wicki A, Hermann F, Prêtre V, et al. Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: The prospective AVALUE cohort study. Oncol Res Treat. 2014 37(5):230-6.
30. Kimmick GG, Lenihan DJ, Sawyer DB, Mayer EL, Hershman DL. Cardiotoxicity of Anticancer Therapies. Cardio-Oncology Clin Overl Cancer Hear Dis. 2017:vii-viii.
31. Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 2017;18(8).
32. Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. npj Precis Oncol. 2017;1(1):31.
33. Mohamed A, Hassan A, Qureshi K, et al. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart J. 2018;70:S96-S100.
34. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058-1067.
35. Sawaya H, Sebag IA, Plana JC, et al. Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. Am J Cardiol. 2011;107(9):1375.
36. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol. 2016 Mar;13(3):172-84.
37. Gershwin ME, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Ann Intern Med. 1974 Apr;80(4):531-40.
38. Quezado ZMN, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993 Jan 1;118(1):31-6.
39. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Physiol. 2017 Jun;280(6):C1358-66.
40. Field JJ, Kanakkanthara A, Miller JH. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorganic Med Chem. 2015 Sep 15;22(18):5050-9.
41. Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: A phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov;8(11):3360-8.
42. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974-984.
43. Pudełek K, Pudełek J, Nawrocki S. Cardiotoxicity in breast cancer patients after radiotherapy – modern methods of minimizing the dose to the heart and dilemmas of choosing critical cardiac structures for monitoring dose distribution. OncoReview. 2016 6(3):A113-11.
44. Jacobse JN, Duane FK, Boekel NB, et al. Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors Radiation Oncology. Int J Radiat Oncol Biol Phys. 2019;103(3):595-604.
45. Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs supine positioning for breast cancer radiotherapy. JAMA - J Am Med Assoc. 2012 Sep 5;308(9):861-3.
46. Raj KA, Evans ES, Prosnitz RG, et al. Is there an increased risk of local recurrence under the heart block in patients with left-sided breast cancer? Cancer J. 2006 Jul-Aug;12(4):309-17.
47. Canney PA, Sanderson R, Deehan C, Wheldon T. Variation in the probability of cardiac complications with radiation technique in early breast cancer. Br J Radiol. 2001 Mar;74(879):262-5.
48. Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. J Clin Oncol. 2016 Apr 1;34(10):1122-30.
49. Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20(5):816-827.
50. Caron J, Nohria A. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This? Curr Oncol Rep. 2018 Jun 6;20(8):61.
51. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.
52. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017 Mar 10;35(8):893-911.
53. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.
54. Clasen SC, Wald JW. Left Ventricular Dysfunction and Chemotherapeutic Agents. Curr Cardiol Rep. 2018;20(4):20.
55. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4;63(8):809-16.
56. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003 Feb;49(2):248-52.
57. Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. 24 2017 Nov;24(6):774-782.
58. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282-S4295.
59. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013 Jan 8;61(1):77-84.
60. Gripp E de A, Oliveira GE de, Feijó LA, Garcia MI, Xavier SS, Sousa AS de. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment. Arq Bras Cardiol. 2018;110(2):140-150. doi:10.5935/abc.20180021
61. Ghosh AK, Walker JM. Cardio-Oncology – A new subspecialty with collaboration at its heart. Indian Heart J. 2017;69(4):556.
62. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017 Nov 14;70(20):2536-2551.
63. Abdel-Rahman O, Alorabi M. Expert Review of Anticancer Therapy Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. 2015;15(7):829-37.
64. Lenihan DJ, Rodriguez Muñoz D, Lyon AR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-2801.
65. Radulescu L, Dan Radulescu, Parv Andreea, Duncea Caius, Ciuleanu T, Mitrea Paulina. Cardioprotective role of lisinopril and rosuvastatin in the prevention of anthracycline induced cardiotoxicity. European Journal of Echocardiography 2011; 12(suppl_2):ii14–ii44; P316; https://doi.org/10.1093/ejechocard/jer206
66. Guimaraes GV, das Dores Cruz F, Higuchi-dos-Santos MH, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity. J Am Coll Cardiol. 2018 May 22;71(20):2281-2290.
67. Gulati G, Heck SL, Røsjø H, et al. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. J Am Heart Assoc. 2017;6(11).
68. Cochera F, Dinca D, Bordejevic DA, et al. Cancer Management and Research Dovepress Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. 2018 Jul 16;10:2071-2081.
69. Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014 Apr 22;3(2):e000665.
70. Lu J, Li J, Hu Y, et al. Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation. Acta Pharm Sin B. 2019 9(2):433–442.
71. Kirkham AA, Davis MK. Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors. J Oncol. 2015;2015:1-13.
72. Mazza R, Maggioni AP, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126-137.
73. Yusuf SW, Venkatesulu BP, Mahadevan LS, Krishnan S. Radiation-Induced Cardiovascular Disease: A Clinical Perspective. Front Cardiovasc Med. 2017;4(October):1-7.
74. Tarantini L, Massimo Gulizia M, Di Lenarda A, et al. ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: Executive summary. Eur Hear Journal, Suppl. 2017;19:D370-D379.
75. Ghosh AK, Walker JM. Cardio-Oncology – A new subspecialty with collaboration at its heart. Indian Heart J. 2017;69(4):556.
76. Tousoulis D. Cardio-oncology: Novel concepts and directions. Hell J Cardiol. 2017;58(3):175-177.